Aktiia Secures FDA Clearance, $42M Series B and Profitable Growth as It Rebrands to Hilo

New updates have been reported about Aktiia.

Aktiia closed 2025 with a series of milestones that materially strengthen its regulatory position, capital base and commercial trajectory, positioning the Swiss company as a leading player in preventive cardiovascular technology. The company secured FDA clearance for its G0 Hilo band, the first cuffless, continuous blood pressure monitoring device approved for over-the-counter use in the U.S., opening the door to the world’s largest consumer health market. Aktiia also completed a $42 million Series B round co-led by Earlybird Health and Wellington Partners, with new and existing investors bringing total funding above $100 million, providing capital to accelerate U.S. expansion, R&D and commercialization. During the year, the company rebranded its product portfolio under the Hilo name to create a unified “blood pressure intelligence” platform focused on early detection and long-term prevention, and it launched Hilo in Australia, extending its footprint to a third major region after Europe and North America.

Operationally, Aktiia reported a record year of profitable growth, with revenue acceleration in the fourth quarter as it scaled commercial operations across 12 markets and strengthened market presence in key regions. The company deepened its role in national hypertension strategies by publishing its first UK Blood Pressure Report and entering a formal Prevention Partners agreement as a Gold Partner with the British & Irish Hypertension Society, aligning its platform with evidence-based public health initiatives. Scientifically, Aktiia completed 10 conference papers and journal manuscripts supporting continuous, cuffless monitoring and AI-driven blood pressure estimation, and Hilo deployed a new algorithm that increases reading density and reliability in real-world conditions, enhancing the value of its data for both consumers and clinicians. The appointment of Stefan Petzinger as CEO capped a strategic reset aimed at scaling preventive cardiovascular solutions globally. Entering 2026, Aktiia plans to build on its strengthened product platform and innovation pipeline by expanding regulatory pathways and reimbursement access, deeper integration of Hilo into clinical workflows, and further real-world prevention research—aiming to make proactive hypertension management a default standard of care rather than an exception.